Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
CSBA Letter to Congressional Leaders on PBM, PPRV…
Dear Congressional Leaders:On behalf of the Council of State Bioscience Associations (CSBA)—a national coalition of independent, state and territory-based organizations representing the full breadth of America’s biotechnology ecosystem—we write to…
BIO's Comments on Advisory Committee on…
Re: Docket No. CDC-2025-0783; Advisory Committee on Immunization Practices (ACIP) MeetingDear Dr. Zadeh and Members of the ACIP:The Biotechnology Innovation Organization (BIO) appreciates the opportunity to provide comments to the Advisory Committee…
Testimony of BIO President & CEO John F. Crowley…
Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000…
All Letters, Testimony & Comments
  • Show All
Search
Results
April 27, 2021
On behalf of the Biotechnology Innovation Organization (BIO), the global industry organization representing the biotechnology industry, I want to express support for House Bill 1091, which recently passed the Washington Legislature. BIO member…
April 23, 2021
We write to you in strong support of President Biden’s nomination of Jewel Bronaugh, PhD to serve as Deputy Secretary of Agriculture and ask that you quickly approve her nomination. As leaders of the nation’s food and agricultural organizations, we…
April 9, 2021
The Biotechnology Innovation Organization (BIO) submitted the below comments to the National Institute of Standards and Technology on proposed revisions to regulations that would further the Return on Investment (ROI) Initiative for Unleashing…
April 6, 2021
On Tuesday, April 6th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s January 2021 draft industry guidance on “Human Gene Therapy for Neurodegenerative Diseases.” In its comments, BIO stated that while the guidance covers…
April 2, 2021
Dear Secretary Buttigieg, National Climate Advisor McCarthy, and Director Deese: The undersigned organizations, representing aviation industry stakeholders including passenger and cargo carriers, business and general aviation, aircraft and engine…
March 26, 2021
On Friday, March 26th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s public meeting announcement titled, “Best Practices for Development and Application of Disease Progression Models.” BIO appreciates that FDA is seeking…
March 26, 2021
The Biotechnology Innovation Organization is delighted to support the Inventor Diversity for Economic Advancement Act of 2021 and urge swift enactment of this important measure.
March 24, 2021
The Biotechnology Innovation Organization is pleased to submit a statement for the record to the United States House of Representatives Committee on Science and Technology and Space and Aeronautics Subcommittee hearing entitled, "Examining R&D…
March 22, 2021
I write today on behalf of the Biotechnology Industry Organization (BIO) – the world’s largest biotechnology trade group – to urge you to put Senate Bill 11 – the New Mexico Clean Fuel Standard Act – on the agenda for the March 31 special session of…
March 18, 2021
The Biotechnology Innovation Organization (BIO) is pleased to submit a statement for the record to the United States House of Representatives Committee on Energy and Commerce Subcommittee on Environment and Climate Change hearing entitled, "The…